177 related articles for article (PubMed ID: 24127439)
1. BIRC5 (survivin) splice variant expression correlates with refractory disease and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group.
Moore AS; Alonzo TA; Gerbing RB; Lange BJ; Heerema NA; Franklin J; Raimondi SC; Hirsch BA; Gamis AS; Meshinchi S
Pediatr Blood Cancer; 2014 Apr; 61(4):647-52. PubMed ID: 24127439
[TBL] [Abstract][Full Text] [Related]
2. In vivo expression of survivin and its splice variant survivin-2B: impact on clinical outcome in acute myeloid leukemia.
Wagner M; Schmelz K; Wuchter C; Ludwig WD; Dörken B; Tamm I
Int J Cancer; 2006 Sep; 119(6):1291-7. PubMed ID: 16619249
[TBL] [Abstract][Full Text] [Related]
3. Survivin' Acute Myeloid Leukaemia-A Personalised Target for inv(16) Patients.
Greiner J; Brown E; Bullinger L; Hills RK; Morris V; Döhner H; Mills KI; Guinn BA
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638823
[TBL] [Abstract][Full Text] [Related]
4. Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation.
Pfrepper C; Klink A; Behre G; Schenk T; Franke GN; Jentzsch M; Schwind S; Al-Ali HK; Hochhaus A; Niederwieser D; Sayer HG
J Cancer Res Clin Oncol; 2016 Jan; 142(1):317-24. PubMed ID: 26424692
[TBL] [Abstract][Full Text] [Related]
5. The outcomes of relapsed acute myeloid leukemia in children: Results from the Japanese Pediatric Leukemia/Lymphoma Study Group AML-05R study.
Moritake H; Tanaka S; Miyamura T; Nakayama H; Shiba N; Shimada A; Terui K; Yuza Y; Koh K; Goto H; Kakuda H; Saito A; Hasegawa D; Iwamoto S; Taga T; Adachi S; Tomizawa D
Pediatr Blood Cancer; 2021 Jan; 68(1):e28736. PubMed ID: 32991072
[TBL] [Abstract][Full Text] [Related]
6. Cytoplasmic localization of wild-type survivin is associated with constitutive activation of the PI3K/Akt signaling pathway and represents a favorable prognostic factor in patients with acute myeloid leukemia.
Serrano-López J; Serrano J; Figueroa V; Torres-Gomez A; Tabares S; Casaño J; Fernandez-Escalada N; Sánchez-Garcia J
Haematologica; 2013 Dec; 98(12):1877-85. PubMed ID: 23812937
[TBL] [Abstract][Full Text] [Related]
7. Comparable survival for pediatric acute myeloid leukemia with poor-risk cytogenetics following chemotherapy, matched related donor, or unrelated donor transplantation.
Kelly MJ; Horan JT; Alonzo TA; Eapen M; Gerbing RB; He W; Lange BJ; Parsons SK; Woods WG
Pediatr Blood Cancer; 2014 Feb; 61(2):269-75. PubMed ID: 23955900
[TBL] [Abstract][Full Text] [Related]
8. Treatment outcome in older patients with childhood acute myeloid leukemia.
Rubnitz JE; Pounds S; Cao X; Jenkins L; Dahl G; Bowman WP; Taub JW; Pui CH; Ribeiro RC; Campana D; Inaba H
Cancer; 2012 Dec; 118(24):6253-9. PubMed ID: 22674050
[TBL] [Abstract][Full Text] [Related]
9. Minimally differentiated acute myeloid leukemia (FAB AML-M0) is associated with an adverse outcome in children: a report from the Children's Oncology Group, studies CCG-2891 and CCG-2961.
Barbaric D; Alonzo TA; Gerbing RB; Meshinchi S; Heerema NA; Barnard DR; Lange BJ; Woods WG; Arceci RJ; Smith FO
Blood; 2007 Mar; 109(6):2314-21. PubMed ID: 17158236
[TBL] [Abstract][Full Text] [Related]
10. Survivin delta Ex3 overexpression in thyroid malignancies.
Waligórska-Stachura J; Andrusiewicz M; Sawicka-Gutaj N; Biczysko M; Jankowska A; Kubiczak M; Czarnywojtek A; Wrotkowska E; Ruchała M
PLoS One; 2014; 9(6):e100534. PubMed ID: 24945990
[TBL] [Abstract][Full Text] [Related]
11. Comparison of clinical remission and survival between CLAG and FLAG induction chemotherapy in patients with refractory or relapsed acute myeloid leukemia: a prospective cohort study.
Bao Y; Zhao J; Li ZZ
Clin Transl Oncol; 2018 Jul; 20(7):870-880. PubMed ID: 29181696
[TBL] [Abstract][Full Text] [Related]
12. Comparison of a fludarabine and melphalan combination-based reduced toxicity conditioning with myeloablative conditioning by radiation and/or busulfan in acute myeloid leukemia in Japanese children and adolescents.
Ishida H; Adachi S; Hasegawa D; Okamoto Y; Goto H; Inagaki J; Inoue M; Koh K; Yabe H; Kawa K; Kato K; Atsuta Y; Kudo K
Pediatr Blood Cancer; 2015 May; 62(5):883-9. PubMed ID: 25545836
[TBL] [Abstract][Full Text] [Related]
13. Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure.
Wattad M; Weber D; Döhner K; Krauter J; Gaidzik VI; Paschka P; Heuser M; Thol F; Kindler T; Lübbert M; Salih HR; Kündgen A; Horst HA; Brossart P; Götze K; Nachbaur D; Köhne CH; Ringhoffer M; Wulf G; Held G; Salwender H; Benner A; Ganser A; Döhner H; Schlenk RF
Leukemia; 2017 Jun; 31(6):1306-1313. PubMed ID: 28138160
[TBL] [Abstract][Full Text] [Related]
14. Acute myeloid leukemia derived from lympho-myeloid clonal hematopoiesis.
Thol F; Klesse S; Köhler L; Gabdoulline R; Kloos A; Liebich A; Wichmann M; Chaturvedi A; Fabisch J; Gaidzik VI; Paschka P; Bullinger L; Bug G; Serve H; Göhring G; Schlegelberger B; Lübbert M; Kirchner H; Wattad M; Kraemer D; Hertenstein B; Heil G; Fiedler W; Krauter J; Schlenk RF; Döhner K; Döhner H; Ganser A; Heuser M
Leukemia; 2017 Jun; 31(6):1286-1295. PubMed ID: 27881874
[TBL] [Abstract][Full Text] [Related]
15. Mito-FLAG with Ara-C as bolus versus continuous infusion in recurrent or refractory AML--long-term results of a prospective randomized intergroup study of the East German Study Group Hematology/Oncology (OSHO) and the Study Alliance Leukemia (SAL).
Thiel A; Schetelig J; Pönisch W; Schäfer-Eckart K; Aulitzky W; Peter N; Schulze A; Maschmeyer G; Neugebauer S; Herbst R; Hänel A; Morgner A; Kroschinsky F; Bornhäuser M; Lange T; Wilhelm M; Niederwieser D; Ehninger G; Fiedler F; Hänel M; ;
Ann Oncol; 2015 Jul; 26(7):1434-40. PubMed ID: 25922062
[TBL] [Abstract][Full Text] [Related]
16. Expression of antiapoptotic proteins livin and survivin in pediatric AML patients, as prognostic markers.
Zareifar S; Ghorbani S; Monabbati A; Bordbar MR; Zekavat OR; Abdolkarimi B; Haghpanah S
Pediatr Hematol Oncol; 2018 May; 35(4):250-256. PubMed ID: 30588872
[TBL] [Abstract][Full Text] [Related]
17. Outcome of pediatric patients with acute myeloid leukemia (AML) and -5/5q- abnormalities from five pediatric AML treatment protocols: a report from the Children's Oncology Group.
Johnston DL; Alonzo TA; Gerbing RB; Hirsch B; Heerema NA; Ravindranath Y; Woods WG; Lange BJ; Gamis AS; Raimondi SC
Pediatr Blood Cancer; 2013 Dec; 60(12):2073-8. PubMed ID: 24039149
[TBL] [Abstract][Full Text] [Related]
18. Distinct prognostic values of Annexin family members expression in acute myeloid leukemia.
Niu Y; Yang X; Chen Y; Jin X; Xie Y; Tang Y; Li L; Liu S; Guo Y; Li X; Duan L; Wang H
Clin Transl Oncol; 2019 Sep; 21(9):1186-1196. PubMed ID: 30694461
[TBL] [Abstract][Full Text] [Related]
19. High expression levels of x-linked inhibitor of apoptosis protein and survivin correlate with poor overall survival in childhood de novo acute myeloid leukemia.
Tamm I; Richter S; Oltersdorf D; Creutzig U; Harbott J; Scholz F; Karawajew L; Ludwig WD; Wuchter C
Clin Cancer Res; 2004 Jun; 10(11):3737-44. PubMed ID: 15173080
[TBL] [Abstract][Full Text] [Related]
20. Reduced-intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Baron F; Labopin M; Peniket A; Jindra P; Afanasyev B; Sanz MA; Deconinck E; Nagler A; Mohty M
Cancer; 2015 Apr; 121(7):1048-55. PubMed ID: 25424330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
